When the dust settles: What did we learn from the bexarotene discussion?

Alzheimer's Research and Therapy

Volumn 5, Issue 6, 2013, Pages

  Tesseur, Ina ^a,b   De Strooper, Bart ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BEXAROTENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALZHEIMER DISEASE; COGNITION; DRUG FORMULATION; FEAR; FOLLOW UP; GENETIC RISK; INTERSTITIAL FLUID; LIPID METABOLISM; LIVER WEIGHT; LONG TERM MEMORY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RECOGNITION; REVIEW; SPATIAL MEMORY; TREATMENT DURATION; UPREGULATION; WEIGHT REDUCTION;

EID: 84887877229     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt218     Document Type: Review

References (14)

1. Apolipoprotein E mimetics and cholesterol-lowering properties. Sharifov OF, Nayyar G, Garber DW, Handattu SP, Mishra VK, Goldberg D, Anantharamaiah GM, Gupta H, Am J Cardiovasc Drugs 2011 11 371 381 10.2165/11594190-000000000-00000 22149316
2. Apolipoprotein E sets the stage: response to injury triggers neuropathology. Mahley RW, Huang Y, Neuron 2012 76 871 885 10.1016/j.neuron. 2012.11.020 23217737
3. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Liu CC, Kanekiyo T, Xu H, Bu G, Nat Rev Neurol 2013 9 106 118 10.1038/nrneurol. 2012.263 23296339
4. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE, Science 2012 335 1503 1506 10.1126/science.1217697 22323736
5. FDA, Targretin Drug Approval Package [ http://www.accessdata.fda.gov/ drugsatfda-docs/nda/99/21055-Targretin.cfm ]
6. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, Staels B, Tailleux A, Arterioscler Thromb Vasc Biol 2009 29 1488 1495 10.1161/ATVBAHA.109.189506 19592467
7. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS, Science 2013 340 924-f 23704555
8. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B, Science 2013 340 924-e 23704554
9. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM, Science 2013 340 924-d 23704553
10. Correction: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. LaClair KD, Manaye KF, Lee DL, Allard JS, Savonenko AV, Troncoso JC, Wong PC, Mol Neurodegener 2013 8 26 10.1186/1750-1326-8-26
11. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Fitz NF, Cronican AA, Lefterov I, Koldamova R, Science 2013 340 924-c 23704552
12. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM, Mol Neurodegener 2013 8 13 10.1186/1750-1326-8-13 23601557
13. Drugs.com, Targretin [ http://www.drugs.com/uk/targretin-capsules-1302. html ]
14. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models" Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA, Science 2013 340 924-g 23704556